Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice.

Fundam Clin Pharmacol · 2022 · PMC9545784 · PMID 35470467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Phase II and Phase III studies on the safety and efficacy of EDB versus edaravone in patients with AIS showed a positive trend of improved functional outcomes when administered of EDB within 48 h after AIS and 90 days after AIS [ 20 , 21 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.